HA- CGRP MAb DI Flashcards

1
Q

CGRP MAbs used in HA treatment

A

Eptinezumab, erenumab, fremanezumab, galcanezumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Eptinezumab brand name

A

Vyepti

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Erenumab brand name

A

Almovig

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fremanezumab brand name

A

Ajovy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Galcanezumab brand name

A

Emgality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Eptinezumab indication

A

Migraine PREVENTION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Erenumab indication

A

Migraine PREVENTION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Fremanezumab indication

A

Migraine PREVENTION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Galcanezumab indications

A

Migraine PREVENTION and PREVENTION OF CLUSTER HA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Eptinezumab route of administration and frequency

A

IV q3months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Erenumab route of administration and frequency

A

SQ qmonth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Fremanezumab route of administration and frequency

A

SQ month or q3months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Galcanezumab route of administration and frequency

A

SQ qmonth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Eptinezumab ADEs

A

INFUSION reaction, nasopharyngitis, nausea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Erenumab ADEs

A

Injection site reaction, constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fremanezumab ADE

A

Injection site reaction

17
Q

Galcanezumab ADE

A

Injection site reaction

18
Q

CGRP MAb DDI

A

Few drug interactions (specifically efgartigimod)

19
Q

CGRP MAb warning/precaution

A

Caution in patients with recent CV or cerebrovascular ischemic events

20
Q

CGRP MAb half-life

A

Around 28-32 days

21
Q

Adequate trial of eptinezumab

A

≥6 months

22
Q

Adequate trial of erenumab, fremanezumab, galcanezumab

A

≥3 months